Minerva Neurosciences | NERV - Aktuelle Verpflichtungen





Aktuelle Verpflichtungen Veränderung Datum
Acadia Pharmaceuticals USD 361.44M 55.91M 2026-06
Adma Biologics USD 75.76M 2.22M 2026-06
ALKERMES USD 662.09M 62.59M 2026-06
Alterity Therapeutics Limited AUD 1.73M 2.77M 2025-12
AstraZeneca USD 31.55B 1.02B 2026-06
BioCryst Pharmaceuticals USD 208.85M 13.46M 2026-06
Bristol-Myers Squibb USD 18.66B 499M 2026-06
Cipla INR 70.14B 7.16B 2026-03
Clal Biotechnology ILS 6.66M 3.75M 2023-12
Compugen USD 22.04M 533K 2026-03
CSL USD 4.61B 207M 2025-12
Eli Lilly USD 47.74B 11.11B 2026-06
GlaxoSmithKline GBP 21.53B 895M 2026-06
Grifols EUR 2.37B 156.97M 2025-12
Halozyme Therapeutics USD 344.44M 18.77M 2026-06
Ionis Pharmaceuticals USD 315.64M 401.36M 2026-06
J&J USD 54.9B 2.82B 2026-06
Merck USD 27.73B 786M 2026-06
Minerva Neurosciences USD 2.29M 381K 2025-12
Neurocrine Biosciences USD 874.5M 42.8M 2026-06
Novartis USD 31.75B 374M 2026-06
Novavax USD 330.57M 11.89M 2026-06
Pfizer USD 32.65B 1.7B 2026-06
Roche Holding CHF 28.85B 846M 2026-06
Sanofi EUR 31.93B 1.92B 2026-06
Takeda JPY 2.76T 335.02B 2026-06
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12